In patients with type 2 diabetes (T2DM), early glycemic control is essential to reduce cardiovascular risk, and prevent microvascular complications and neuropathy. New treatments, such as glucagon-like peptide-1 receptor agonists and their fixed-ratio combinations support a physiologic approach to glycemic control while lessening the risk of hypoglycemia and weight gain. Clinical data also support the role of these new agents in patients with cardiovascular disease and chronic kidney disease. This case-based activity explores recent guideline-based treatment pathways, individualization of glycemic goals based on patient characteristics, and tailoring treatments based on patient factors and comorbidities.
Interactive case study
After completing this activity, participants should be better able to:
- Describe evidence for early and aggressive intervention in T2DM, including evidence for its benefits in long-term protection and preservation of β-cell function
- Incorporate strategies that support a physiologic approach to glycemic control
- Formulate individualized treatment plans to address challenges of glycemic control, clinical inertia, and patient adherence
NPs and PAs
Continuing Nursing Education Provider Unit, Boston University School of Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
This educational activity has been provided by Continuing Nursing Education Provider Unit, Boston University School of Medicine and jointly provided by Practicing Clinicians Exchange.
Contact hours: 1.0, which are eligible for 1.0 pharmacology credits.
Course director: Jason Worcester, MD, Boston University School of Medicine
CNE course advisor: Claire Murphy, MSN, NP-C, Boston University School of Medicine
This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. Approval is valid for one year from 3/31/2019. PAs should only claim credit commensurate with the extent of their participation.
This series was cosupported by educational grants from AbbVie Inc.; Actelion Pharmaceuticals US, Inc.; Amgen; Biogen; Genentech; Novartis Pharmaceuticals Corporation; Sanofi US; Sanofi US and Regeneron Pharmaceuticals; and Teva Pharmaceuticals.
This activity is supported by an independent educational grant from Sanofi US.
The opinions or views expressed in this continuing education activity are those of the faculty and do not necessarily reflect the opinions or recommendations of the American Academy of Physician Assistants, Boston University School of Medicine, Continuing Education Alliance, Practicing Clinicians Exchange, or any educational supporter.
THIS CONTINUING MEDICAL EDUCATION PROGRAM IS INTENDED SOLELY FOR EDUCATIONAL PURPOSES FOR QUALIFIED HEALTH CARE PROFESSIONALS. IN NO EVENT SHALL BOSTON UNIVERSITY BE LIABLE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE INFORMATION CONTAINED IN THE PROGRAM. IN NO EVENT SHOULD THE INFORMATION CONTAINED IN THE PROGRAM BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE. NO PHYSICIAN-PATIENT RELATIONSHIP IS BEING ESTABLISHED.
Boston University School of Medicine asks all individuals involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all relevant relationships with commercial interests. This information is disclosed to CME activity participants. Boston University School of Medicine has procedures to resolve any apparent conflicts of interest. In addition, faculty members are asked to disclose when any discussion of unapproved use of pharmaceuticals and devices is being discussed.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration.
Ms Kruger: advisory board: Abbott, Dexcom, Lilly, Intarcia, Janssen, Novo Nordisk, Sanofi Aventis; grants/research support: Abbott, AstraZeneca, Dexcom, Lilly, Helmsley Charitable Trust, Lexicon, Novo Nordisk; speakers bureau: Abbott, AstraZeneca, Boehringer Ingelheim/Lilly, Dexcom, Insulet, Janssen, Lilly, Novo Nordisk, Valeritas; stock: Dexcom.
The Planning Committee for this activity included Claire Murphy, MSN, NP-C, Carmela A. Townsend, DNP, MS/MBA, RN, Jason Worcester, MD, Jody Walker, MS, and Julie L. White, MS, of Boston University School of Medicine; and Warren Beckman, Ruth Cohen, and Craig Borders of Practicing Clinicians Exchange. None of the aforementioned members of the Planning Committee have any relevant relationships to disclose.
Participants wishing to earn CE/CME credit must:
- Read the content
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 70%.
The estimated time to complete this activity is 1.00 hours.
Release date: March 31, 2019
Expiration date: March 30, 2020
Any internet connected computer or mobile device with any of the following browsers:
Internet Explorer, Google Chrome, Mozilla Firefox, Safari
© 2019 Practicing Clinicians Exchange. All Rights Reserved. CPCE93318-7C